A murine experimental anthracycline extravasation model: Pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage

Autor: Thougaard, Annemette V., Langer, Seppo W., Hainau, Bo, Grauslund, Morten, Juhl, Birgitte Ravn, Jensen, Peter Buhl, Sehested, Maxwell

Publikováno v: In Toxicology 2010 269(1):67-72

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Autor: Christensen Mette K, Imai Shin-Ichiro, Yoshino Jun, Kiess Wieland, Garten Antje, Petersen Jakob G, Olesen Uffe H, Fristrup Peter, Thougaard Annemette V, Björkling Fredrik, Jensen Peter B, Nielsen Søren J, Sehested Maxwell

Publikováno v: BMC Cancer, Vol 10, Iss 1, p 677 (2010)

Abstract Background Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to thes

Externí odkaz: https://doaj.org/article/fa4b3650926e431fa6039c81f84b1fdf

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells

Autor: Dejligbjerg Marielle, Grauslund Morten, Litman Thomas, Collins Laura, Qian Xiaozhong, Jeffers Michael, Lichenstein Henri, Jensen Peter, Sehested Maxwell

Publikováno v: Molecular Cancer, Vol 7, Iss 1, p 70 (2008)

Abstract Background Histone acetylation is an epigenetic modification involved in the regulation of gene expression, balanced by histone acetyl transferases and histone deacetylase (HDAC) enzymes. HDAC inhibitors (HDACi) induce growth arrest and cell

Externí odkaz: https://doaj.org/article/4a18a18256784c919c41bca9abe7035a

N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance

Autor: Jensen, Lars H ^*, Wessel, Irene, Møller, Marianne, Nitiss, John L, Sehested, Maxwell, Jensen, Peter B

Publikováno v: In FEBS Letters 2000 480(2):201-207

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation and SAR

Autor: Christensen, Mette Knak, Erichsen, Kamille Dumong, Olesen, Uffe Hogh, Tjørnelund, Jette, Fristrup, Peter, Thougaard, Annemette, Nielsen, Søren Jensby, Sehested, Maxwell, Jensen, Peter B., Loza, Einars, Kalvinsh, Ivars, Garten, Antje, Kiess, Wieland, Bjorkling, Fredrik

Publikováno v: Christensen, M K, Erichsen, K D, Olesen, U H, Tjørnelund, J, Fristrup, P, Thougaard, A, Nielsen, S J, Sehested, M, Jensen, P B, Loza, E, Kalvinsh, I, Garten, A, Kiess, W & Bjorkling, F 2013, ' Nicotinamide phosphoribosyltransferase inhibitors, design, preparation and SAR. ', Open Journal of Medicinal Chemistry, vol. 56, no. 22, pp. 9071–9088 . https://doi.org/10.1021/jm4009949

Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. Using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1202::6d16ac5e268da00fc8271a5a5d274e81
https://orbit.dtu.dk/en/publications/8e5e62d2-f055-48a3-a61d-8a832abf5ee3